VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Inclusion criteria: * Confirmed diagnosis of symptomatic MM based on standard criteria. * No prior or current systemic therapy for MM, including steroids. * At least 18 years and less than 65 years of age. * Presence of quantifiable M protein in serum (e.g. greater than 1 g/dL for IgG MM, greater than 0.5 g/dL of IgA or IgD MM) or urine (e.g. greater than 200 mg/day for BJ MM). * Karnofsky performance status (PS) at least 60%. * Willing and able to comply with the protocol requirements. * Agreement from both male and female patients to follow the risk management program established for the prevention of pregnancy, including double methods for contraception and beta-HCG tests for women of childbearing potential and contraception for males. * Adequate organ function, including heart, liver, kidney (serum creatinine less than 2 mg/dL) * Platelet count at least 70 x 10/mcL and absolute neutrophil count at least 1 x 10/mcl Exclusion criteria: * Diagnosis of asymptomatic MM or of MGUS based on standard criteria. * Diagnosis of non-secretory MM. * Diagnosis of AL Amyloidosis. * Prior or current systemic therapy for MM, including steroids (with exception of bisphosphonates). * Patient has received other investigational drugs within 30 days before enrollment. * Female subjects pregnant or breastfeeding * Patient has Grade 2 or higher peripheral neuropathy (NCI criteria). * Patient has a prior history of thrombosis or venous thromboembolism or pulmonary embolism. * Patient has a previous diagnosis of antiphospholipid antibodies or lupus anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin, protein C or S deficiency. * Patient has a clear indication to receive a specific other anti-platelet therapy (e.g. clopidogrel, ticlopidine). * Patient has a clear indication to receive long-term anticoagulant therapy (e.g. prosthetic heart valve, atrial fibrillation). * Active bleeding or high risk of bleeding (gastrointestinal bleeding within the past 12 months; endoscopic diagnosis of peptic ulcer disease or ulcerative esophagitis within the past 6 months unless there is documented endoscopic evidence of healing; intracranial bleeding within the past year; amyloidosis; known bleeding diathesis). * Seropositive for HIV, or active hepatitis A, B or C infection. * Poorly controlled hypertension or diabetes mellitus (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before the start of therapy) or other serious medical or psychiatric conditions that could interfere with adherence to or completion of this study. * Patient has hypersensitivity to bortezomib, boron or mannitol. * Serious medical or psychiatric illness likely to interfere with participation in this clinical study * Previous or concurrent malignancies at other sites, with the exception of appropriately treated localized epithelial skin or cervical cancer. Patients with remote histories (\>5 years) of other cured tumors may be entered. * Receipt of extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy within 4 weeks before enrolment.